| dc.description.abstract | Introduction: Propolis, as a natural product with antitumor properties, is
considered to have potential as an apoptotic agent against osteosarcoma cells
through the regulation of Bcl-2, Bax, and caspase-3 expression, but the
effectiveness of Indonesian propolis on U2OS cell lines has not been widely
studied. This study aims to assess the effectiveness of Indonesian propolis as an
apoptosis inducer in osteosarcoma cells (U2OS) by comparing the expression of
Bax, Bcl-2, and caspase-3 when given doxorubicin (standard therapy), propolis, and
a combination of propolis with doxorubicin.
Methods: This study used U2OS osteosarcoma cell cultures cultured in DMEM
media with the addition of FBS, L-glutamine, and antibiotics, and through the
process of thawing, subculture, and planting into well plates. The combination of
propolis and doxorubicin was then tested on U2OS cells to assess the synergistic
effect on viability and apoptotic gene expression using the MTT assay and RT-PCR
methods.
Results: This study showed that 10% propolis and 5 μM doxorubicin has significant
differences in optical density parameters, inhibition, and Bax and Bcl-2 gene
expression (p < 0.001) between groups. The combination of both also increased Bax
expression and decreased Bcl-2 expression, but did not provide a significant
difference in caspase-3 expression between groups (p = 0.75).
Conclusion: This study shows that propolis has significant anticancer effects
against osteosarcoma cells by increasing Bax expression, decreasing Bcl-2
expression, and inhibiting cell viability, especially in the combination of 10%
propolis and 5 μM doxorubicin. However, in vivo research is still needed in the
form of pharmacokinetic and pharmacodynamic tests on experimental animals. | en_US |
